Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment determined by physician Clear all
Completed No phase listed Observational Results available

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

NCT01088503
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
ADP receptor inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
185
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 3, 2026, 10:55 AM EDT
Terminated Phase 4 Interventional Results available

99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients

NCT03065218
View directory record Official record
Conditions
Thyroid Cancer
Interventions
99mTc sestamibi
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

Baroreflex Activation Therapy for Heart Failure

NCT02627196
View directory record Official record
Conditions
Heart Failure
Interventions
BAROSTIM NEO® System, Medical Management
Device · Drug
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
88
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Recruiting Not applicable Interventional

Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes

NCT06297980
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
Interventions
Personalized modifications to treatment to address menstrual cycle effects on glycemia
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional

Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas

NCT00443196
View directory record Official record
Conditions
Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
MiCK Assay
Procedure
Lead sponsor
Pierian Biosciences
Industry
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 3, 2026, 10:55 AM EDT
Suspended Phase 2 Interventional

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

NCT06044311
View directory record Official record
Conditions
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
Interventions
Vactosertib, Standard of Care Preoperative Therapy
Drug
Lead sponsor
Melissa Lumish
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational Results available

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil, Non-Treprostinil PAH Medications
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Timeline
2019
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • Santa Barbara, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 3, 2026, 10:55 AM EDT
Active, not recruiting Phase 2 Interventional

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Drug · Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

NCT02954536
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
pembrolizumab, trastuzumab, capecitabine, cisplatin, Oxaliplatin, 5-Fluorouracil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational

Anti-TNF Therapy for Refractory Colitis in Hospitalized Children

NCT02799615
View directory record Official record
Conditions
Colitis, Ulcerative, Bowel Diseases, Inflammatory
Interventions
Infliximab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Atlanta, Georgia • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 3, 2026, 10:55 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

NCT04637594
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
377
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

Piloting Healthcare Coordination in Hypertension

NCT02988193
View directory record Official record
Conditions
Hypertension
Interventions
optima4BP Medication Management
Device
Lead sponsor
Optima Integrated Health
Industry
Eligibility
21 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 3, 2026, 10:55 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Targeting ER Stress in Vascular Dysfunction

NCT04001647
View directory record Official record
Conditions
Vasodilation, Arterial Stiffness
Interventions
Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 3, 2026, 10:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

NCT04131504
View directory record Official record
Conditions
Crohn's Disease, IBD
Interventions
Infliximab, Adalimumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 22 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
4
States / cities
Hartford, Connecticut • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

NCT00833833
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Aspirin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 3, 2026, 10:55 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT03693014
View directory record Official record
Conditions
Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Interventions
Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Radiation · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Recruiting Phase 2 Interventional

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

NCT01837329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 3, 2026, 10:55 AM EDT
Recruiting Not applicable Interventional

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis

NCT05301101
View directory record Official record
Conditions
Solid Tumor
Interventions
Re-irradiation
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Improving Antimicrobial Prescribing Practices in the Neonatal ICU

NCT03079245
View directory record Official record
Conditions
Infants in Neonatal Intensive Care Units
Interventions
Education Plus (E+), Clinical Decision Support, Prescriber Audit and Feedback
Other
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
6,184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Wilmington, Delaware • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection

NCT01873573
View directory record Official record
Conditions
Dysphagia
Interventions
Dilation, Triamcinolone Injection, Esophagogastroduodenoscopy (EGD)
Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 3, 2026, 10:55 AM EDT
Terminated Phase 4 Interventional Results available

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 3, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain

NCT00869245
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
OU - Cardiac MRI, OU - Conventional Care Testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 3, 2026, 10:55 AM EDT